Psilocybin Microdosing on Cognition, Mood and Quality of Life

Inclusion Criteria:

* No history of psychedelic use OR
* No use within 10 years, less than or equal to 7x in life OR
* No use within 5 years, less than or equal to 3x in life
* Able to read, speak, and understand English
* Able and willing to provide written informed consent, and willing to commit to study protocol
* Women of childbearing potential must be on a highly effective birth control method
* Must have smartphone compatible with mindLAMP app

Exclusion Criteria:

* Positive screen for recreational drugs or alcohol on test day will result in rescheduling the appointment
* Current mood, developmental, or psychotic disorders (e.g., schizophrenia, affective disorders) per DSM-V
* Current or past alcohol or substance use disorder per DSM-V
* IQ \<70 on the Weschler Abbreviated Scale of Intelligence
* Serious medical, neuro-ophthalmological, or neurological illness (e.g., cancer, seizure disorders, encephalopathy)
* Current pregnancy, breastfeeding, or ineffective birth control methods
* History of head trauma with loss of consciousness lasting \>30 minutes or concussion in last 30 days
* Any medical/neurological condition that could compromise neurocognitive performance (e.g., epilepsy, multiple sclerosis, fetal alcohol syndrome)
* Anyone deemed unsafe to study personnel for any reason; e.g., suicidal ideation
* Focal brain lesion seen on structural MRI
* MRI contraindications (e.g., implanted metallic object, severe claustrophobia)
* Clinically significant risk of suicidality, as determined by a score of 4 or higher on the suicidal ideation subscale of C-SSRS (past 6 months) or any suicidal behavior (lifetime)
* Currently taking a monoamine oxidase inhibitor, tricyclic antidepressant, other non-SSRI or non-SNRI antidepressants, an antipsychotic or a mood stabilizer
* Family history of schizophrenia or schizoaffective disorder (first degree relatives), or bipolar disorder type 1 (first degree relatives)
* Diagnosis of arrhythmia or ongoing cardiovascular disorder
* Sustained clinically relevant abnormal heart rate (resting supine heart rate \>100 bpm) or blood pressure (resting supine sustolic blood pressure (SBP) above 140mmHg or diastolic blood pressure (DBP) above 90mmHg) at screening
* Clinically relevant abnormal laboratory results, 12-lead ECG, vital signs, cardiopulmonary compromise as detected by echocardiogram, or other physical findings
* Presence of more than mild regurgitant lesions in any position and left ventricular ejection fraction \< 35 %
* Evidence of pulmonary vascular disease demonstrated by right ventricular systolic pressure \>30mmHg
* Currently taking any GLP-1

Study Discontinuation Criteria

* Development of active suicidal or homicidal ideation with plan and intent
* Worsening in mood symptoms, or development of psychotic symptoms that in the opinion of the investigators requires discontinuation
* Development of severe or life-threatening medical condition
* Psychiatric or medical hospitalization or incarceration post-screening
* Adverse reaction to study drug that in the opinion of the investigators requires discontinuation (e.g. acute, clinically significant hypertension, cardiac toxicity, non-acute significant negative psychological changes)